BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

828 related articles for article (PubMed ID: 29129488)

  • 1. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
    Ai Y; Lu X; Zhu T; Zhu Y; Liu H; Sun S
    Medicine (Baltimore); 2020 Dec; 99(50):e23606. PubMed ID: 33327329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
    Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
    Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
    Loh ML
    Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.
    Yahng SA; Kim M; Kim TM; Jeon YW; Yoon JH; Shin SH; Lee SE; Eom KS; Lee S; Min CK; Kim HJ; Kim DW; Lee JW; Min WS; Kim YJ
    Oncotarget; 2017 Feb; 8(7):12342-12354. PubMed ID: 27729615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
    Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
    Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
    Chang TY; Dvorak CC; Loh ML
    Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
    Niemeyer CM; Kratz CP
    Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes].
    Strullu M; Leblanc T; Lainey E
    Bull Cancer; 2023 Nov; 110(11):1183-1195. PubMed ID: 37453833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.